By Puyaan Singh April 27 (Reuters) - Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for ...

Hemab Therapeutics Holdings Inc., a clinical-stage biotechnology company, is seeking to raise as much as $212 million in a US initial public offering.

This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen ...

Apr 27, 2026--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that th ...

Century Therapeutics (IPSC) analysis: autoimmune CAR-cell pivot, CNTY-813 Type 1 diabetes upside, cash burn cuts, rNPV fair ...

(NASDAQ:KYMR) is among the best biotech stocks. TheFly reported on April 13 that KYMR announced that the U.S. Food and Drug ...

A Woburn biotechnology company laid off more than 200 Massachusetts employees last week, and state filings warn more cuts may ...

This business acquisition appears to be a genetic match: Colossal Biosciences, the company that brought back the dire wolves, has acquired Viagen Pets and Equine, which has cloned dogs for Paris ...

Shares of several pharmaceutical companies were up after President Trump signed an executive order aimed at accelerating research, development access to psychedelic medicines for the treatment of ...

Rossari Biotech reported a 33.43% year-on-year rise in Q4FY26 net profit to ₹46 crore, supported by 18.2% revenue growth to ...

With an uptick and increasingly even spread of capital across the space, the BIA’s Martin Turner is optimistic for British ...